



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Raymond G. Goodwin et al.

Attorney Docket No.: 2801-C

Serial No.: 08/910,449

Group Art Unit: 1646

Filed: August 5, 1997

Examiner: L. Spector

For: 4-1BB POLYPEPTIDES AND DNA ENCODING 4-1BB POLYPEPTIDES

TECH CENTER 1600/2900

H71
Plunk
10/28/00

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449. Copies of the publications identified as "OTHER DOCUMENTS" and "U.S. PATENT DOCUMENTS" on the attached Form PTO-1449 are not provided because they were cited or submitted to the PTO in connection with application serial nos. 08/060,843 and 08/236,918. Copies of the following PCT and Canadian applications are enclosed:

1. PCT/US94/10457
2. Canadian application no. 2,108,401

Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application. Applicant authorizes the Commissioner to charge Applicant's deposit account no. 09-0089, Pursuant to 37 C.F.R. 1.97(c), the fee of \$240 set forth in 37C.F.R 1.17(p). A copy of this Statement is enclosed for accounting purposes.

Respectfully submitted,

Janis C. Henry
Janis C. Henry
Attorney for Applicant
Reg. No. 34,347

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: October 12, 2000

Signed: *Elizabeth M. McCarthy*
Elizabeth M. McCarthy

10/23/2000 VWHN11 00000060 090089 08910449
01 FC:126 240.00 CH

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2801-C

SERIAL NO.

08/910 449

RECEIVED

APPLICANT

Raymond G. Goodwin et al.

OCT 25 1997

FILING DATE

August 5, 1997

GROUP

1646

DATED

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,675,285	06/23/87	Clark, et al.	435/6		
	5,030,576	07/09/91	Dull, et al.	435/69		
	5,217,880	6/8/93	Mitta, et al.	435	69.1	3/23/92
	5,312,733	5/17/94	MacLeod	435	69.1	4/11/91

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
2,108,401	10/14/93	Canada			
PCT/US94/10457	9/15/94	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Kwon, B. and Weissman, S., "cDNA sequences of two inducible T-cell genes", <i>Proc. Natl. Acad. Sci. USA</i> , 86:1963-1967, March 1989.
	Kwon, B. et al., "Expression Characteristics of Two Potential T Cell Mediator Genes", <i>Cellular Immunology</i> , 121:414-422, 1989.
	Kwon, B. et al., "Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones," <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2896-2900, May 1987.
	Pollok, K. et al., "Inducible T Cell Antigen 4-1BB", <i>The Journal of Immunology</i> , 150: 771-781, February 1, 1993.
	Mallet, S. and Barclay, A.N., "A new superfamily of cell surface proteins related to the nerve growth factor receptor", <i>Immunology Today</i> , 12:220-223, 1991.
	Schwartz et al., "cDNA Sequence Tissue Distribution and Regulation of Expression of a New Member of the Human TNF-NGF Receptor Family", <i>Arthritis Rheum.</i> 35 (9 Suppl.), Abstract D63, page S224, 1992.
	Schwartz et al., "Identification of a New Member of the Human Nerve Growth Factor/Tumor Necrosis Factor Receptor Family," <i>J. Immunology</i> 150: 298A, Abstract No. 1705, 1993.
	Chalupny, N. et al., "T-cell activation molecule 4-1BB binds to extracellular matrix proteins", <i>Proc. Natl. Acad. Sci. USA</i> , 89:10360-64, November 1992.
	Flanagan, J. and Leder, P., "The <i>kit</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts", <i>Cell</i> 63:185-194, October 5, 1990

DATE CONSIDERED

EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK


ATTY. DOCKET NO.

2801-C

SERIAL NO.

08/910,449

OFFICE



INFORMATION DISCLOSURE CITATION

(Supplemental Sheet)

APPLICANT

Raymond G. Goodwin, et al.

FILING DATE

August 5, 1997

GROUP

1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Aruffo, A. and Seed, B., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system", *Proc. Natl. Acad. Sci. USA* 84: 8573-8577, December 1987

Capon, D., et al., "Designing CD4 immunoadhesins for AIDS therapy", *Nature* 337: 525-531, 9 February 1989

Steele, R.E., "Factor hunting made easier", *TIBS* 16:125-126, April 1991

Armitage, R., et al., "Molecular and biological characterization of a murine ligand for CD40", *Nature* 357: 80-82 (1992)

Hollenbaugh, D., et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity", *The Embo Journal* 11: 4313-4321 (1992)

Ohtsuka, E., et al., "An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Neoxynosine at Ambiguous Codon Positions," *Journal of Biol. Chemistry* 260: (5) 2605-2608, 1985

Frohman, M., et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," *Proc. Natl. Acad. Sci. USA*, 85:8998-9002, 1998.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.